Proinflammatory cytokine production in HaCaT cells treated by eosin: Implications for the topical treatment of psoriasis

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 1067-1075

  Zampetti, A ^a   Mastrofrancesco, A ^b   Flori, E ^b   Maresca, V ^b   Picardo, M ^b   Amerio, P ^b   Feliciani, C ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Eosin; IL 6; IL 8; Psoriasis; TNF alpha

Indexed keywords

EOSIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; HUMAN; HUMAN CELL; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN DISEASE; SKIN INFLAMMATION; TOPICAL TREATMENT;

EID: 76349093830     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200423     Document Type: Article

References (32)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3:121-8.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664-75.
3. Chamian F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in phatogenesis. Curr Opin Rheumatol 2004; 16:331-7.
4. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanism in psoriasis. Clin Exp Immunol 2004; 135:1-8.
5. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med 1994; 45:491-503.
6. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86:6367-71.
7. Ohta Y, Katayama I, Funato T, Yokozeki H, Nishiyama S, Hirano T, Kishimoto T, Nishioka K. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Res 1991; 283:351-6.
8. Gillitzer R, Berger R, Mielke V, Müller C, Wolff K, Stingl G. Upper keratinocyte of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol 1991; 97:73-9.
9. Boukamp P, Petrussevska RT, Breitkreuz D, Hornung J, Marjham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106:761-71.
10. Boelsma E, Verhoeven MC, Ponec M. Reconstruction of a human skin equivalent using a spontaneously transformed keratinocyte cell line (HaCaT). J Invest Dermatol 1999; 112:489-98.
11. Partridge M, Chantry D, Turner M, Feldmann M. Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell line. J Invest Dermatol 1991; 96:771-6.
12. Konur A, Schulz U, Eissner G, Andreesen R, Holler E. Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production. Br J Dermatol 2005; 152:1134-42.
13. Coffey RJ, Derynch R, Wilcox JN, Bringman TS, Goustin AS, Moses HL, Pittelkow MR. Production and auto-induction of TGF alpha in human keratinocytes. Nature 1987; 328:817-20.
14. Owsianowski M, Busch FW, Bonnekoh B, Orfanos CE. Long-term cultured adult human keratinocytes secrete granulocyte-macrophage colony-stimulating factor but not interleukin-3 after cytokine exposure in vitro. Skin Pharmacol 1991; 4:158-64.
15. Winiski AP, Foster CA. ICAM-1 expression in a spontaneously transformed human keratinocytes cell line: characterization by a simple cell-ELISA assay. J Invest Dermatol 1992; 99:48-52.
16. Shohat M, Mimouni M, Varsano I. Efficacy of topical application of glucocorticosteroids compared with eosin in infants with seborrheic dermatitis. Cutis 1987; 40:67-8.
17. Arad A, Mimouni D, Ben-Amitai D, Zeharia A, Mimouni M. Efficacy of topical application of eosin compared with zinc oxide paste and corticosteroid cream for diaper dermatitis. Dermatology 1999; 199:319-22.
18. Monafo WW, Freedman B. Topical therapy for burns. Surg Clin North Am 1987; 67:133-45.
19. Zampetti A, Barone A, Antuzzi D, Amerio P, Tulli A, Feliciani C, Amerio P. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years. J Dermatolog Treat 2008; 19:134-40.
20. Tabolli S, Alessandroni L, Didona B, Di Pietro C, Gisondi P, Rota L, Sampogna F, Abeni D. A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clin Exp Dermatol 2008; 34:304-8.
21. Paulukat J, Bosmann M, Nold M, et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol 2001; 167:7038-43.
22. Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 2005; 4:329-34.
23. Madonna S, Scarponi C, De Pità O, Albanesi C. Suppressor of cytokine signaling 1 inhibits IFN-γ inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation FASEB 2008; 22:3287-97.
24. Teunissen MB, Koomen CW, Jansen J, de Waal Malefyt R, Schmitt E, Van den Wijngaard RM, Das PK, Bos JD. In contrast to their murine counterparts, normal human keratinocytes and human epidermoid cell lines A431 and HaCat fail to express IL-10 mRNA and protein. Clin Exp Immunol 1997; 107:213-23.
25. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33:45-56.
26. Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd SL, Terlecky SR. Reactive oxygen species in tumor necrosis factor-α-Activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 2008; 128:2606-14.
27. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175:2721-9.
28. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM.. Localization of tumor necrosis factor alpha (TNF α) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993; 94:354-62.
29. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 2004; 13:193-22.
30. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13:357-68.
31. Yao M, Zhou RH, Petreaca M, Zheng L, Shyy J, Martins-Green M. Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8 induced angiogenesis. J Leukoc Biol 2006; 18:608-20.
32. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152:597-615.